Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyPresbyterian Hypoglossal Nerve Coverage | OpenPaye…
    Ask Trek AI about this page
    ModifiedPresbyterian Health PlanPolicy 46.0

    Hypoglossal Nerve Stimulator

    Customize your policy alerts

    Sign up for Presbyterian Health Plan Policy 46.0 alerts

    Get alerted when Policy 46.0 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage, prior authorization, medical necessity, provider qualifications, and coding for hypoglossal nerve stimulation used to treat obstructive sleep apnea for Presbyterian Health Plan members in Medicare, Medicaid, and commercial lines of business.

    Policy Summary
    PayerPresbyterian Health Plan
    PolicyHypoglossal Nerve Stimulator
    Policy CodePolicy 46.0
    Change TypeModified
    Effective DateN/A
    Last ReviewAug 27, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for CPT 64582, 64583, and 64584 before hypoglossal nerve stimulator procedures.
    SourceLink
    POLICY UPDATE CHANGES

    In August 2025, the policy removed its homegrown adult and pediatric criteria and adopted MCG A-0973 for both populations.

    In August 2024, the adult BMI criterion was corrected to less than 40 and the pediatric BMI criterion was corrected to less than the 95th percentile for age.

    In October 2023, the policy changed from following LCD L38385 to homegrown criteria, including revised adult criteria and new criteria for adolescents aged 13 through 17 with Down syndrome and obstructive sleep apnea.

    In February 2024, the policy clarified that one sleep study after hypoglossal nerve implantation is allowed and subsequent studies require medical director review for medical necessity.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    RequiredUtilization management requirement
    MCG A-0973Coverage criteria source
    1Allowed post-implantation sleep studies
    BMI >= 40Adult contraindication threshold
    3Procedure codes requiring prior authorization

    Coverage Criteria

    Covered Indications for Adults

    Covered adult indications are determined under the current MCG A-0973 criteria, subject to the limitations in this policy.

    ALL of the following

    • The member meets the current MCG A-0973 covered-indication criteria for adults.
    • All applicable limitations, contraindications, place-of-service requirements, and provider-qualification requirements in this policy are satisfied.

    Covered Indications for Adolescents

    Covered adolescent indications are determined under the current MCG A-0973 criteria, subject to the limitations in this policy.

    ALL of the following

    • The member meets the current MCG A-0973 covered-indication criteria for adolescents.
    • All applicable limitations, contraindications, place-of-service requirements, and provider-qualification requirements in this policy are satisfied.

    Place of Service and Provider Qualifications

    Hypoglossal nerve stimulation for the treatment of obstructive sleep apnea must be furnished in accordance with accepted standards of medical practice and in a setting appropriate to the patient's medical needs and condition.

    ALL of the following

    • The procedure is furnished in an appropriate place of service consistent with the patient's medical needs and condition and accepted standards of medical practice.
    • Insertion is performed by a qualified physician (MD or DO) who is board certified or board eligible in otolaryngology, has completed an appropriate AMA- or AOA-certified residency and/or fellowship program, and maintains ongoing certification in otolaryngology.
    • Before implanting an FDA-approved device, the surgeon has completed classroom instruction from the FDA-approved device manufacturer or equivalent and cadaver training in device-implant techniques; documentation of satisfactory training completion is maintained for review.
    • Sleep physicians and sleep technicians who evaluate, refer, perform post-implant evaluation, or titrate the device have completed appropriate classroom and hands-on training, and documentation of satisfactory training completion or board-approved competency is maintained for review.

    Current MCG A-0973 Criteria

    Presbyterian Health Plan follows the current MCG A-0973 criteria for both adult and adolescent hypoglossal nerve stimulation coverage, subject to the limitations in this policy.

    ALL of the following

    • The member meets the applicable current MCG A-0973 covered-indication criteria for adults or adolescents, as applicable.
    • The applicable MCG A-0973 criteria are applied together with the limitations, contraindications, place-of-service requirements, and provider-qualification requirements stated in this policy.

    Hypoglossal nerve neurostimulation is not medically reasonable and necessary for all indications other than the covered adult and adolescent indications determined under the current MCG A-0973 criteria and the requirements of this policy.

    Non-FDA-approved hypoglossal nerve neurostimulation is not medically reasonable and necessary for the treatment of adult obstructive sleep apnea because of insufficient evidence that it is safe and effective.

    Central and mixed apneas comprise more than one-quarter of the total apnea-hypopnea index (AHI).

    An implantable device could experience unintended interaction with the hypoglossal nerve stimulation (HGNS) implant system.

    For adults, body mass index (BMI) is equal to or greater than 40.

    Neuromuscular disease; hypoglossal-nerve palsy; severe restrictive or obstructive pulmonary disease; moderate-to-severe pulmonary arterial hypertension; severe valvular heart disease; or New York Heart Association class III or IV heart failure.

    Recent myocardial infarction or severe cardiac arrhythmias within the past 6 months, or persistent uncontrolled hypertension despite medication use.

    Active, serious mental illness that reduces the ability to perform activities of daily living (ADLs) and could interfere with the patient's ability to operate the HNS and report problems to the attending provider.

    Coexisting nonrespiratory sleep disorders that would confound functional sleep assessment.

    The member is pregnant or plans to become pregnant.

    The member requires magnetic resonance imaging (MRI) with model 3024. Members requiring MRI with model 3028 may undergo MRI of the head and extremities only when the conditions and precautions in the manufacturer guidelines are met; manufacturer guidelines for this and future models must be followed.

    The member is unable, or lacks the necessary assistance, to operate the sleep remote.

    A condition or procedure has compromised neurological control of the upper airway.

    An anatomical finding could compromise device performance, such as tonsil size 3 or 4 according to the tonsillar hypertrophy grading scale.

    Coverage is limited to the covered adult and adolescent indications under the current MCG A-0973 criteria and the applicable requirements of this policy.

    Any service that does not satisfy the applicable medical-necessity criteria, contraindication exclusions, place-of-service requirements, or provider-qualification requirements is not reasonable and necessary and will be denied.

    Post-Implantation Sleep Studies

    One sleep study after hypoglossal nerve implantation is allowed. Any additional post-implantation sleep study requires Medical Director Review (MDR) for medical necessity.

    ALL of the following

    • No more than one sleep study is performed after hypoglossal nerve implantation without additional review.
    • Any additional post-implantation sleep study is submitted for MDR review and supported by documentation of medical necessity.

    Coding and Clinical Thresholds

    CPT codesCPT
    64582Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
    64583Revision or replacement of hypoglossal nerve neurostimulator array and distal respiratory sensor electrode or electrode array, including connection to existing pulse generator.
    64584Removal of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array.
    Current procedure codes requiring prior authorizationCPTCovered
    64582Hypoglossal nerve stimulator procedure code requiring prior authorization
    64583Hypoglossal nerve stimulator procedure code requiring prior authorization
    64584Hypoglossal nerve stimulator procedure code requiring prior authorization
    Historical or deleted procedure codesCPTNot Covered
    64568Former hypoglossal nerve stimulator code removed from the article and policy
    0466TCode deleted by the AMA on January 1, 2022 and removed from the policy and prior authorization grid
    0467TCode deleted by the AMA on January 1, 2022 and removed from the policy and prior authorization grid
    0468TCode deleted by the AMA on January 1, 2022 and removed from the policy and prior authorization grid
    OPPS packaged device codesHCPCS
    C1767OPPS device code with payment packaged into payment for other services
    C1778OPPS device code with payment packaged into payment for other services
    C1787OPPS device code with payment packaged into payment for other services
    Central and Mixed Apnea Proportion
    Contraindication thresholdCentral and mixed apneas comprising more than one-quarter of the total AHI
    Clinical statusContraindication to hypoglossal nerve neurostimulation
    Applies toMembers being evaluated for hypoglossal nerve neurostimulation
    Adult BMI
    Contraindication thresholdBMI equal to or greater than 40
    PopulationAdults

    Provider Requirements and Authorization

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for applicable hypoglossal nerve stimulator services across all lines of business.

    • Applies to Commercial, Medicaid, and Medicare lines of business.
    Prior Authorization

    Authorization for Hypoglossal Nerve Stimulator Procedures

    Prior authorization is required for hypoglossal nerve stimulator procedures billed under CPT 64582, 64583, or 64584.

    • CPT 64582
    • CPT 64583
    • CPT 64584

    Clinical Background

    Obstructive sleep apnea (OSA) is characterized by recurrent obstruction of the upper airway during sleep. It is associated with hypertension, cardiovascular disease, arrhythmia, cerebrovascular disease, excessive daytime sleepiness, and mood disorders. Continuous positive airway pressure (CPAP) is the primary treatment, but some patients cannot tolerate it, creating a need for alternative therapies. Hypoglossal nerve stimulation uses a breathing sensor and an implanted stimulation system to stimulate the tongue muscles and maintain upper-airway patency during sleep.

    Definitions

    Hypoglossal Nerve Stimulation (HGNS)
    DefinitionAn implanted system that senses breathing patterns and delivers mild stimulation to the hypoglossal nerve
    MechanismStimulation moves the tongue forward and maintains upper-airway patency during sleep
    Implantable componentsStimulation lead, breathing sensor lead, and generator
    Complete Concentric Collapse (CCC)
    DefinitionComplete concentric collapse of the upper airway
    Identification methodIdentified during Drug Induced Sleep Endoscopy
    Clinical context
    Policy Summary
    PayerPresbyterian Health Plan
    PolicyHypoglossal Nerve Stimulator
    Policy CodePolicy 46.0
    Change TypeModified
    Effective DateN/A
    Last ReviewAug 27, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for CPT 64582, 64583, and 64584 before hypoglossal nerve stimulator procedures.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical ThresholdsProvider Requirements and AuthorizationClinical BackgroundDefinitions
  1. Except for expected postoperative care by the inserting physician, evaluation, referral, and post-implant evaluation are performed by a board-certified or board-eligible sleep physician qualified under LCD L35050, Outpatient Sleep Studies.
  2. Sleep technicians meet the qualifications outlined in LCD L35050, Outpatient Sleep Studies.
  3. Sleep studies are performed in an accredited sleep facility as stated in LCD L35050, Outpatient Sleep Studies.
  4. The member's specific benefit plan and Schedule of Benefits are reviewed because benefits may vary by Presbyterian Health Plan product.
  5. Clinical statusContraindication to hypoglossal nerve neurostimulation
    Recent Myocardial Infarction or Severe Cardiac Arrhythmia
    Contraindication windowWithin the past 6 months
    ConditionsRecent myocardial infarction or severe cardiac arrhythmias
    Clinical statusContraindication to hypoglossal nerve neurostimulation
    DISE Manufacturer Validation
    Required agreementAt least 80% agreement
    Consecutive studiesAt least 15 consecutive studies
    Validation methodFDA-approved manufacturer's second-opinion service of validation via video clip submissions
    Adult Age
    Minimum age18 years
    PopulationAdults
    Coverage criterionAdult coverage criteria use an age of ≥ 18 years
    Adult BMI
    BMI criterionLess than 40 kg/m2
    PopulationAdults
    Coverage criterionAdult coverage requires BMI < 40 kg/m2
    Adult AHI, RDI, or REI
    Respiratory event index15 ≤ AHI/RDI/REI ≤ 100 events per hour
    Measures includedApnea-hypopnea index (AHI), respiratory disturbance index (RDI), or respiratory event index (REI)
    PopulationAdults
    Adult Central Apneas
    Maximum proportionLess than 25% central apneas
    MeasureCentral apneas as a proportion of the apnea-hypopnea index
    PopulationAdults
    Adolescent Age
    Covered age range13 to 17 years
    PopulationAdolescents
    Coverage criterionAdolescent coverage criteria apply to members aged 13 through 17 years
    Pediatric BMI
    BMI criterionLess than the 95th percentile for age
    PopulationPediatric members
    Measurement basisAge-specific BMI percentile
    Pediatric AHI
    AHI range≥ 10 and ≤ 50 events per hour
    MeasureApnea-hypopnea index (AHI)
    PopulationPediatric members
    Pediatric Central Apneas
    Maximum proportionLess than 25% central apneas
    MeasureCentral apneas as a proportion of the apnea-hypopnea index
    PopulationPediatric members
    Documentation Required

    Retain DISE Validation Records

    For Drug Induced Sleep Endoscopy (DISE), retain documentation showing the inserting provider’s required manufacturer validation and be prepared to submit it to the contractor when requested.

    • Retain the manufacturer second-opinion validation documentation.
    • Validation is based on video clip submissions demonstrating at least 80% agreement in at least 15 consecutive studies.

    Unsupported block type: documentation

    Documentation Required

    Document Device Implant Training

    Before implanting an FDA-approved hypoglossal nerve stimulation device, surgeons must complete manufacturer or equivalent classroom instruction on implant techniques and cadaver training.

    • Retain manufacturer documentation supporting completion of training to an exemplary level.
    Documentation Required

    Document Sleep Personnel and Facility Qualifications

    Document the qualifications and training of the sleep physician, sleep technician, and facility involved in evaluation, titration, and post-implant care.

    • Evaluation, referral, and post-implant evaluation must be performed by a board-eligible or board-certified sleep physician meeting LCD L35050 qualifications, excluding expected postoperative care by the inserting physician.
    • Sleep technicians must meet the qualifications outlined in LCD L35050, Outpatient Sleep Studies.
    • Sleep studies must be performed in an accredited sleep facility as specified in LCD L35050.
    • Sleep physicians and technicians must complete classroom and hands-on training on device titration and operation, with completion records retained for review.
    Documentation Required

    Verify Implanting Physician Qualifications

    The implanting physician must be qualified to perform hypoglossal nerve stimulation and maintain documentation of the required education, credentials, experience, and ongoing competency.

    • Must be an MD or DO who is board certified or board eligible in otolaryngology and has completed an appropriate residency and/or fellowship program.
    • Must maintain ongoing certification in otolaryngology and complete an AMA- or AOA-certified otolaryngology residency program.

    Unsupported block type: documentation

    Denial Risk

    Noncovered Indications and Devices

    Hypoglossal nerve neurostimulation is not medically reasonable and necessary for indications other than the covered indication or when using a system that is not FDA approved for adult obstructive sleep apnea.

    • Non-FDA-approved hypoglossal nerve neurostimulation systems are not medically reasonable and necessary for adult obstructive sleep apnea.
    • Requests for other indications may be denied.
    Denial Risk

    Screen for Clinical Contraindications

    Screen for clinical contraindications before requesting authorization. Coverage may be denied when any listed contraindication is present.

    • Central and mixed apneas comprise more than one-quarter of the total AHI.
    • An implantable device could interact unintentionally with the hypoglossal nerve stimulation system.
    • BMI is equal to or greater than 40 for adults.
    • Neuromuscular disease, hypoglossal-nerve palsy, or severe restrictive or obstructive pulmonary disease.
    • Moderate-to-severe pulmonary arterial hypertension, severe valvular heart disease, or NYHA class III or IV heart failure.
    • Myocardial infarction or severe cardiac arrhythmias within the past 6 months.
    • Persistent uncontrolled hypertension despite medication.
    • Active serious mental illness that limits activities of daily living or could interfere with device operation or reporting problems.
    Denial Risk

    Evaluate Additional Contraindications

    Additional contraindications must also be evaluated and documented before authorization. Any applicable exclusion may result in denial as not medically reasonable and necessary.

    • Coexisting nonrespiratory sleep disorders that would confound functional sleep assessment.
    • Current pregnancy or plans to become pregnant.
    • Need for MRI with model 3024; model 3028 MRI is limited to the head and extremities when manufacturer conditions and precautions are met.
    • Inability to operate the sleep remote or lack of necessary assistance to operate it.
    • A condition or procedure compromising neurological control of the upper airway.
    • Anatomical findings that could compromise device performance, such as tonsil size 3 or 4 due to tonsillar hypertrophy.
    Documentation Required

    Meet DISE Validation Requirements

    The inserting provider must meet the manufacturer’s DISE certification requirements because of documented inconsistency in identifying complete concentric collapse (CCC).

    • The provider must be certified by the FDA-approved manufacturer’s second-opinion validation service.
    • Certification requires at least 80% agreement across at least 15 consecutive studies.
    • Maintain documentation demonstrating certification and validation.
    Documentation Required

    Make Shared Decision-Making Records Available

    Shared decision making must be documented as a conversation between the attending provider and the patient. Providers must make the record available to the contractor upon request.

    • The documentation must identify or otherwise establish the attending provider’s participation.
    • A discussion only among multiple providers does not satisfy the shared decision-making requirement.
    Prior Authorization

    Additional Post-Implant Titration Studies

    One in-laboratory sleep study with titration is allowed after hypoglossal nerve implantation. Any additional post-implant in-lab titration study requires Medical Director Review (MDR) for medical necessity.

    • Additional requests beyond the one allowed study require MDR review.
    • Submit clinical information supporting the medical necessity of any additional study.
    Denial Risk

    Failure to Meet Coverage Criteria

    Authorization may be denied when the member does not meet the applicable coverage criteria. Presbyterian Health Plan or the medical director may request additional information supporting medical necessity during review.

    • Submit records demonstrating that all applicable criteria are met.
    • Additional medical-necessity information may be provided or requested for case review.
    DISE evaluation of upper-airway anatomy for hypoglossal nerve stimulation
    Shared Decision Making (SDM)
    DefinitionA documented conversation between an attending provider and the patient
    What it excludesIt is not a conversation between multiple providers
    Documentation requirementProviders shall provide the documentation if requested by the contractor